- Comprehensive ELUXA trial programme explores olmutinib* (BI 1482694) as a monotherapy and in several combination studies
- Olmutinib will be studied in combination with the immuno-oncology therapy Keytruda®+, second-generation TKI Giotrif®/Gilotrif®**, anti-angiogenic agents Vargatef®*** and Avastin®, and Boehringer Ingelheim's investigational IGF mAb BI 836845****
- Accelerated trial programme underway with ELUXA 1 trial fully enrolled; additional Phase III trials to start soon
Dans la même rubrique :
Mercredi 19 Novembre 2025 - 15:00 Algérie : la BAD salue les grands chantiers lancés |
Mercredi 5 Novembre 2025 - 18:21 Tchad : Star Oil Tchad et Airtel Money s'allient pour accélérer l'inclusion financière |
Mardi 28 Octobre 2025 - 19:45 Tchad : Atelier de Formation sur l'Utilisation des Images par le Volet des Standards des Ménages (EHCVM) |
Menu
Boehringer Ingelheim launches ambitious ELUXA trial programme to broadly investigate promising ...






